Hennion & Walsh Asset Management Inc. Has $1.92 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Hennion & Walsh Asset Management Inc. increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 44.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 109,820 shares of the company’s stock after acquiring an additional 34,040 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.17% of Viridian Therapeutics worth $1,923,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its position in Viridian Therapeutics by 170.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,217 shares of the company’s stock valued at $4,805,000 after buying an additional 197,430 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in Viridian Therapeutics in the 3rd quarter valued at $264,000. Schonfeld Strategic Advisors LLC lifted its position in Viridian Therapeutics by 362.3% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 108,037 shares of the company’s stock worth $1,657,000 after buying an additional 84,670 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Viridian Therapeutics by 25.2% during the 3rd quarter. Wellington Management Group LLP now owns 215,648 shares of the company’s stock worth $3,308,000 after buying an additional 43,349 shares during the last quarter. Finally, StoneCrest Wealth Management Inc. bought a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $605,000.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, June 11th. B. Riley cut shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $25.00 to $20.00 in a research note on Thursday, May 9th. LADENBURG THALM/SH SH lowered shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, May 9th. Oppenheimer decreased their price objective on shares of Viridian Therapeutics from $36.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, May 9th. Finally, HC Wainwright decreased their target price on Viridian Therapeutics from $37.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Viridian Therapeutics Stock Up 1.8 %

VRDN stock opened at $13.01 on Friday. The company has a market cap of $830.30 million, a PE ratio of -2.89 and a beta of 1.03. The company has a quick ratio of 23.99, a current ratio of 23.99 and a debt-to-equity ratio of 0.05. Viridian Therapeutics, Inc. has a 52 week low of $10.93 and a 52 week high of $25.05. The business has a 50-day simple moving average of $13.12 and a 200 day simple moving average of $17.03.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, May 8th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.28. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The business’s revenue for the quarter was down 26.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.61) EPS. Sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -3.61 EPS for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.